Category:
Other Preparations
Standard:
N;
Letrozole is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery.
Strength: 2.5mg.
Letrozole Tablets have got Chinese local GMP certificate and EU GMP, and have MA issued from US-FDA, Japanese PMDA. It was approved by EU and launched in European market in 2012, approved by US FDA and Launched in American market in May, 2013 and approved to get launched in the Japanese market in 2015.
Letrozole Tablets are pharmaceutical-grade solid dosage forms containing letrozole as the active ingredient. Manufactured via high-precision compression technology, the core material ensures consistent dissolution rates and chemical stability under standard storage conditions.